Due to concerns surrounding its effectiveness, the US Food and Drug Administration (FDA) ended the Rare Pediatric Disease Designation (RPDD) programme in late 2024.

Thermo Fisher Scientific has signed an agreement for the acquisition of Sanofi’s steriles manufacturing site in Ridgefield, New Jersey, US.

FDA reviewers have identified high rates of ocular toxicity as GSK looks to place its blood cancer drug back on the market.

In a recent webinar, industry experts explain how real-world data and patient-centric support can shape regulatory success ...

With the aim of being the largest life science sector by 2035 behind only the US and China, the UK government is ramping up commercialisation.

Otsuka Pharmaceutical has signed an agreement to acquire all assets related to Cantargia's early-clinical stage CAN10 programme.

As supply chain disruption persists in pharma, global logistics providers with the expertise to overcome any challenge are essential.

Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, Alyftrek.

The White House’s decision to safeguard $400m in President’s Emergency Plan for AIDS Relief (PEPFAR) funding to support the global human immunodeficiency virus (HIV) emergency provides “hope” to ...

LEO has plans for Spevigo beyond generalised pustular psoriasis as it looks to boost its dermatological pipeline.

Ultragenyx Pharmaceuticals has announced the extension of approval by Health Canada for Evkeeza (evinacumab) for HoFH.